Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases

       Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases

PR Newswire

ROCKVILLE, Md., May 3, 2013

ROCKVILLE, Md., May 3, 2013 /PRNewswire/ --EntreMed, Inc. (Nasdaq: ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced the issuance of a U.S. patent
covering methods of treatment and formulations for its clinical-stage
compound, 2-methoxyestradiol (2ME2).

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

Patent No. 8,399,440, entitled "Disease Modifying Anti-Arthritic Activity of
2-Methoxyestradiol," was granted on March 19, 2013, by the U.S. Patent &
Trademark Office and contains composition and method claims covering the
combination of 2ME2 and methotrexate for the treatment of rheumatic diseases,
including rheumatoid arthritis.

2ME2 is an orally active compound that has antiproliferative, antiangiogenic
and anti-inflammatory properties. The inhibition of angiogenesis is an
important approach to the treatment of both cancer and rheumatoid arthritis.
2ME2 has potential as a single agent in rheumatoid arthritis based on its
antiangiogenic, anti-inflammatory, and anti-osteoclastic (bone resorption)
properties. 2ME2 has also demonstrated positive preclinical results for
multiple sclerosis.

Rheumatic diseases are characterized by inflammation and loss of function in
one or more connecting or supporting structures of the body. Rheumatoid
arthritis (RA) is a rheumatic disease characterized by persistent synovial
tissue inflammation. In time, this persistent inflammation can lead to bone
erosion, destruction of cartilage, and complete loss of joint integrity.

Ken K. Ren, Ph.D., EntreMed's CEO, commented, "This patent further expands the
intellectual property coverage for 2ME2. We have increasing evidence that
2ME2 has anti-inflammatory properties, providing us with potential
opportunities to treat diseases such as rheumatoid arthritis. Clinical trial
activities have previously been conducted with 2ME2 in RA, and in December
2012, preclinical results for 2ME2 were published online in the Early Edition
of Proceedings of the National Academy of Sciences (PNAS). We believe 2ME2
has therapeutic value to the management of multiple sclerosis, RA and possible
other autoimmune disorders and we are currently exploring strategies for the
development of 2ME2 including potential partnership opportunities. EntreMed's
2ME2 patent estate now provides composition, method, use, and formulation
patent coverage through 2022."

About EntreMed

EntreMed is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market. Its lead compound, ENMD-2076, a
selective angiogenic kinase inhibitor, has completed several Phase 1 studies
in solid tumors, multiple myeloma, and leukemia, and is currently completing a
multi-center Phase 2 study in ovarian cancer. EntreMed is currently
conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer and a
Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma. The
Company is headquartered in Rockville, Maryland and has local operations in
Beijing, China. Additional information about EntreMed is available on the
Company's web site at www.entremed.comand in various filings with the
Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action.
ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine
kinase targets in addition to the Aurora A kinase. Aurora kinases are key
regulators of mitosis (cell division), and are often over-expressed in human
cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have
been shown to play important roles in the pathology of several cancers.
ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase
2 trial for ovarian cancer. EntreMed is currently conducting a
dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer
and a Phase 2 study in advanced/metastatic soft tissue sarcoma. ENMD-2076 has
received orphan drug designation from the FDA for the treatment of ovarian
cancer, multiple myeloma and acute myeloid leukemia.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate or future candidates; risks
relating to the need for additional capital and the uncertainty of securing
additional funding on favorable terms; declines in actual sales of Thalomid®
resulting in reduced or no royalty payments; risks associated with our product
candidates; any early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results; uncertainties
relating to preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical development
of any of our products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks). Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition. We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com

SOURCE EntreMed, Inc.

Website: http://www.entremed.com
 
Press spacebar to pause and continue. Press esc to stop.